… for increased glucose levels. Close monitoring of glycaemia is recommended in the initial phase of therapy and in prolonged therapy test for glucosuria should be carries out at regular intervals.
• in patients with impaired hepatic function or progressive liver disease, minor alterations in fluid and electrolyte balance may precipitate hepatic coma.
• hyperuricaemia may occur. Only a minor increase in serum uric acid usually occurs but in cases of prolonged elevation, the concurrent use of a uricosuric agent will reverse the hyperuricaemia.
…
Identical in both labels. Surrounding text shown from Wockhardt UK Ltd.
… ent of hypertension in the third trimester. Administration of Atenolol to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation.
The use of Atenolol in women who are, or may become, pregnant requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters, since beta-blockers, in general, have been associated with a decrease in placental perfusion which may result in intra-uterine deaths, immature and premature deliveries.
Breast-feeding
There is significant accumulation of Atenolol in breast milk.
Neonates born to mothers who are receiving Atenolol at parturition or breast-feeding may be at risk of hypoglycaemi …
Identical in both labels. Surrounding text shown from Ipca Laboratories UK Ltd.
… ent of hypertension in the third trimester. Administration of Tenormin to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation.
The use of Tenormin in women who are, or may become, pregnant requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters, since beta-blockers, in general, have been associated with a decrease in placental perfusion which may result in growth retardation, intra-uterine deaths, abortion, immature and premature deliveries.
Breast-feeding
There is significant accumulation of Tenormin in breast milk.
Neonates born to mothers who are receiving Tenormin at parturition or breast-feeding may be at risk of hypoglycaemi …
Identical in both labels. Surrounding text shown from Atnahs Pharma UK Ltd.
… ent of hypertension in the third trimester. Administration of atenolol to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation.
The use of atenolol in women who are, or may become, pregnant requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters, since beta-blockers, in general, have been associated with a decrease in placental perfusion which may result in growth retardation, intra-uterine deaths, abortion, immature and premature deliveries.
Breast-feeding:
There is significant accumulation of atenolol in breast milk.
Neonates born to mothers who are receiving atenolol at parturition or breast- feeding may be at risk of hypoglycaemi …
… ent of hypertension in the third trimester. Administration of Atenolol to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation.
The use of Atenolol in women who are, or may become, pregnant requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters, since beta-blockers, in general, have been associated with a decrease in placental perfusion which may result in growth retardation, intra-uterine deaths, abortion, immature and premature deliveries.
Breast-feeding
There is significant accumulation of Atenolol in breast milk.
Neonates born to mothers who are receiving Atenolol at parturition or breast-feeding may be at risk of hypoglycaemia …
… uded
Administration of atenolol in pregnancy has been associated with reduced foetal growth. Atenolol has been used under close supervision for the treatment of hypertension in the third trimester.
On the basis of its pharmacological properties, adverse effects may occur in the foetus and newborn infant, if used in the first and second trimesters (especially hypoglycaemia, hypotension and bradycardia). Beta-blockers reduce placental perfusion which may result in intra-uterine deaths, immature and premature deliveries.
Breast-feeding
Atenolol is excreted into breast milk reaching higher concentration than in plasma. A risk in the breastfed child cannot be excluded (beta-blockade). Neonates born to mothers wh …
… ment of hypertension in the third trimester. Administration of atenolol to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation
The use of atenolol in women who are or may become pregnant requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters, since beta-blockers, in general, have been associated with a decrease in placental perfusion which may result in growth retardation, intra-uterine deaths, abortion, immature and premature deliveries.
There is significant accumulation of atenolol in breast milk.
Neonates born to mothers who are receiving atenolol at parturition or breast-feeding may be at risk of hypoglycaemia and bradycardia.
…